# A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

> **NCT04965493** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Loxo Oncology, Inc.** · enrollment: 600 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04965493
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-20
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04965493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04965493, "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04965493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*